Condition: Generalized Myasthenia Gravis · Sponsor: UCB Biopharma SRL
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
This description comes directly from the study's public registry record.
UCB Cares · +18445992273 (USA) · ucbcares@ucb.com
UCB Cares · 001 844 599 2273
Always discuss trial participation with your own doctor first.
| Mg0014 50168 | Chicago, Illinois, United States | Withdrawn |
| Mg0014 50574 | Denton, Texas, United States | Withdrawn |
| Mg0014 40144 | Milan, Italy | Recruiting |
| Mg0014 40774 | Katowice, Poland | Recruiting |
| Mg0014 40218 | Warsaw, Poland | Active Not Recruiting |
| Mg0014 20104 | Seoul, South Korea | Withdrawn |
| Mg0014 20220 | Seoul, South Korea | Recruiting |
| Mg0014 40735 | Glasgow, United Kingdom | Recruiting |
| Mg0014 40736 | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06055959